OBJECTIVE: To measure tenofovir (TFV) concentrations in the male genital tract (GT) after single and multiple doses of tenofovir disoproxil fumarate (TDF) and evaluate the HIV-1 RNA response to monotherapy. DESIGN AND METHODS: A pharmacokinetic study of blood plasma (BP) and GT TFV concentrations in 9 men was conducted after 1 and > or =14 doses of TDF. TFV concentrations were measured by validated high-performance liquid chromatography-ultraviolet or tandem mass spectrometry methods, and HIV-1 RNA was measured using Roche (Roche Molecular Systems, Branchburg, NJ) or bioMerieux (bioMerieux, Durham, NC) kits. RESULTS: TFV GT concentrations were 4.4-fold +/- 5.1-fold higher than BP after dose 1 and 5.1-fold +/- 6.8-fold higher than BP after dose 14. Intracellular GT TFV-diphosphate concentrations were 9.4-fold higher than BP after dose 1 and 17.5-fold +/- 22.6-fold higher after dose 7. After 14 days ofTDF monotherapy, HIV-1 RNA decreased by 0.9 log10 copies/mL in blood and 1.0 log10 copies/mL in the GT. CONCLUSIONS: High TFV concentrations were achieved rapidly in the GT of all subjects after single and multiple doses and potently reduced BP and GT HIV-1 RNA levels.
OBJECTIVE: To measure tenofovir (TFV) concentrations in the male genital tract (GT) after single and multiple doses of tenofovir disoproxil fumarate (TDF) and evaluate the HIV-1 RNA response to monotherapy. DESIGN AND METHODS: A pharmacokinetic study of blood plasma (BP) and GT TFV concentrations in 9 men was conducted after 1 and > or =14 doses of TDF. TFV concentrations were measured by validated high-performance liquid chromatography-ultraviolet or tandem mass spectrometry methods, and HIV-1 RNA was measured using Roche (Roche Molecular Systems, Branchburg, NJ) or bioMerieux (bioMerieux, Durham, NC) kits. RESULTS:TFV GT concentrations were 4.4-fold +/- 5.1-fold higher than BP after dose 1 and 5.1-fold +/- 6.8-fold higher than BP after dose 14. Intracellular GT TFV-diphosphate concentrations were 9.4-fold higher than BP after dose 1 and 17.5-fold +/- 22.6-fold higher after dose 7. After 14 days ofTDF monotherapy, HIV-1 RNA decreased by 0.9 log10 copies/mL in blood and 1.0 log10 copies/mL in the GT. CONCLUSIONS: High TFV concentrations were achieved rapidly in the GT of all subjects after single and multiple doses and potently reduced BP and GT HIV-1 RNA levels.
Authors: R M van Praag; R P van Heeswijk; S Jurriaans; J M Lange; R M Hoetelmans; J M Prins Journal: Clin Infect Dis Date: 2001-09-20 Impact factor: 9.079
Authors: Sanjay U C Sankatsing; Jackie Droste; David Burger; Rieneke M E Van Praag; Suzanne Jurriaans; Joep M A Lange; Jan M Prins Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba Journal: AIDS Date: 2007-09-12 Impact factor: 4.177
Authors: H Chakraborty; P K Sen; R W Helms; P L Vernazza; S A Fiscus; J J Eron; B K Patterson; R W Coombs; J N Krieger; M S Cohen Journal: AIDS Date: 2001-03-30 Impact factor: 4.177
Authors: Arlene S Pereira; Laura M Smeaton; John G Gerber; Edward P Acosta; Sally Snyder; Susan A Fiscus; Richard R Tidwell; Roy M Gulick; Robert L Murphy; Joseph J Eron Journal: J Infect Dis Date: 2002-06-26 Impact factor: 5.226
Authors: Michael Louie; Christine Hogan; Arlene Hurley; Viviana Simon; Chris Chung; Neal Padte; Patrick Lamy; John Flaherty; Dion Coakley; Michele Di Mascio; Alan S Perelson; Martin Markowitz Journal: AIDS Date: 2003-05-23 Impact factor: 4.177
Authors: Julie B Dumond; Kuo H Yang; Racheal Kendrick; Y Sunila Reddy; Angela D M Kashuba; Luigi Troiani; Arlene S Bridges; Susan A Fiscus; Alan Forrest; Myron S Cohen Journal: Antimicrob Agents Chemother Date: 2015-08-03 Impact factor: 5.191
Authors: Mitzi Glover; Valeria Y Hebert; Krystle Nichols; Stephen Y Xue; Taylor M Thibeaux; James A Zavecz; Tammy R Dugas Journal: Antiviral Res Date: 2014-09-27 Impact factor: 5.970
Authors: Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson Journal: AIDS Res Hum Retroviruses Date: 2016-09-19 Impact factor: 2.205
Authors: Julie B Dumond; Y Sunila Reddy; Luigi Troiani; Jose F Rodriguez; Arlene S Bridges; Susan A Fiscus; Geoffrey J Yuen; Myron S Cohen; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731